dr. piotrowska on treatment for egfr-mutant nsclc
Published 4 years ago • 219 plays • Length 1:57Download video MP4
Download video MP3
Similar videos
-
1:40
dr. piotrowska on eligibility criteria for osimertinib in lung cancer treatment
-
0:58
dr. papadimitrakopoulou on treatment options for egfr-mutant nsclc
-
1:37
dr. konduri on treatment options for patients with egfr-mutant nsclc
-
3:47
afatinib therapy for uncommon egfr alterations in nsclc
-
18:44
2020 ttf egfr breakout piotrowska part 2 - current options upon acquired resistance to osimertinib
-
1:37
dr. yu on treatments for egfr-mutant lung cancer
-
11:23
2020 ttf egfr breakout piotrowska part 1 - current options upon acquired resistance to osimertinib
-
15:25
targeted therapies: the future of non-small cell lung cancer (nsclc) treatment?
-
14:30
adjuvant therapy for egfr mutant nsclc
-
0:57
examining the impact of the flaura trial in egfr-mutant nsclc
-
3:28
treating beyond progression in egfr-mutant lung cancer
-
1:25
current treatment recommendations and future directions for egfr-mutant nsclc
-
1:47
dr. pacheco on frontline therapy for patients with egfr-mutant nsclc
-
2:03:01
current and future management of non-small cell lung cancer with an egfr mutation
-
1:16
dr. wakelee on first-line therapy for egfr-mutant lung cancer
-
5:00
options for up-front therapy in egfr-mutant nsclc
-
1:15
dr. aggarwal on triplet therapy in egfr-mutant lung cancer
-
6:08
flaura study: a new standard of care for patients with egfr mutated nsclc
-
58:47
15 years of advances in egfr mutant lung cancer